Bridgeway Capital Management’s ImmunityBio IBRX Stock Holding History

Bridgeway Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,300	Closed	-$92K	–	1333
2020 Q3	$92K	Sell	13,300 -30,000	-69%	-$299K	﹤0.01%	1263
2020 Q2	$532K	Sell	43,300 -10,000	-19%	-$56.5K	0.01%	838
2020 Q1	$154K	Sell	53,300 -55,400	-51%	-$277K	﹤0.01%	1121
2019 Q4	$412K	Buy	+108,700	New	+$185K	0.01%	1051
2019 Q2	–	Sell	-201,400	Closed	-$318K	–	1354
2019 Q1	$318K	Sell	201,400 -50,000	-20%	-$62.8K	﹤0.01%	1137
2018 Q4	$292K	Buy	251,400 +76,400	+44%	+$175K	﹤0.01%	1133
2018 Q3	$648K	Buy	175,000 +75,000	+75%	+$237K	0.01%	1068
2018 Q2	$306K	Buy	+100,000	New	+$370K	﹤0.01%	1247

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bridgeway Capital Management's IBRX Position: Q4 2020 in Review

Bridgeway Capital Management sold out of ImmunityBio (IBRX) in Q4 2020, closing a stake of 13,300 shares — an estimated $92K sold.

Bridgeway Capital Management first reported a position in IBRX in Q2 2018 and held it in 8 quarters. The position peaked at $648K in Q3 2018. 104 funds tracked by Wall St. Rank hold IBRX as of Q4 2020.

Bridgeway Capital Management reported no remaining ImmunityBio position as of Q4 2020 after selling out during the quarter.
Bridgeway Capital Management sold 13,300 ImmunityBio shares in Q4 2020, an estimated $92K.
Bridgeway Capital Management first reported a position in ImmunityBio in Q2 2018 and held it in 8 quarters.
Bridgeway Capital Management's ImmunityBio position peaked at $648K in Q3 2018.
104 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2020.

Based on Bridgeway Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.